Tech Company Financing Transactions
Immunomic Therapeutics Funding Round
Immunomic Therapeutics secured a $61.3 million venture capital round on 5/1/2020. Investors included HLB Co. and private investors.
Transaction Overview
Company Name
Announced On
5/1/2020
Transaction Type
Venture Equity
Amount
$61,300,000
Round
Undisclosed
Investors
HLB Co. (Lead Investor)
Proceeds Purpose
Proceeds will support the acceleration of Immunomic Therapeutics' Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, the expansion of its team and infrastructure to support the future growth of the company.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
15010 Broschart Rd. 250
Hershey, MD 20850
USA
Hershey, MD 20850
USA
Phone
Website
Email Address
Overview
Immunomic Therapeutics, Inc. is developing next generation vaccines focusing on allergy immunotherapy. The Company's first vaccine will be for Japanese Red Cedar, JRC-LAMP-vax.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Hearl
Chief Financial Officer
Eric Winzer
Chief Scientific Officer
Teri Heiland
Vice President
Andrew Eisen
VP - Bus. Development
Sia Anagnostou
VP - Operations
Timothy Coleman
VP - Regulatory Affairs
Louise Peltier
Browse more venture capital transactions:
Prev: 5/1/2020: Nexar venture capital transaction
Next: 5/1/2020: Ontic Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs